Revenue Growth - The total revenue for the year ended December 31, 2023, was HKD 714.3 million, representing a 17.0% increase from HKD 610.3 million in 2022[2]. - Revenue from vision correction services accounted for 99.1% of total revenue, increasing by 17.1% to HKD 707.9 million from HKD 604.8 million in 2022[2]. - The group's total revenue for the year ended December 31, 2023, was HKD 714.3 million, representing a 17.0% increase year-on-year, driven by strong growth in cataract surgeries for presbyopia treatment across Germany, China, Denmark, and the UK[34]. - The total revenue for the year reached HKD 714,289, representing a 17.0% increase from HKD 610,291 in 2022[80]. - The total revenue from training services rose to HKD 5,407, up 83.9% from HKD 2,937 in 2022[80]. - Revenue from crystal replacement surgery in China grew by 83.0% to HKD 72.7 million, contributing significantly to overall revenue growth[104]. - The total revenue from refractive laser surgeries decreased by 4.5% to HKD 235.3 million, primarily due to reduced demand in the UK[133]. Profitability - The gross profit for the year was HKD 335.5 million, a 23.9% increase from HKD 270.8 million in 2022, with a gross margin of 47.0%[12]. - The net profit attributable to the company's owners for 2023 was HKD 131,242,000, reflecting a slight decrease from HKD 133,254,000 in 2022[59]. - The EBITDA for the total group in 2023 was HKD 280,864,000, with a breakdown of HKD 185,551,000 from Germany, HKD 52,874,000 from China, HKD 30,503,000 from Denmark, and HKD 17,811,000 from the UK[78]. - The group achieved record revenue and EBITDA, surpassing previous highs set in 2021[126]. - The group's net profit for the year was HKD 133.3 million, a significant increase of 59.6% compared to HKD 83.5 million in the previous year[170]. - Adjusted net profit after tax for the year was HKD 141.7 million, reflecting a 40.0% increase from HKD 101.2 million in 2022[170]. Expenses and Costs - Employee benefits accounted for approximately 45.3% of total cost of sales, up from 41.5% in 2022, with total cost of sales increasing by 11.6% to HKD 378.8 million[5][7]. - Sales expenses increased by 28.7% to HKD 72.9 million, representing 10.2% of total revenue compared to 9.3% in 2022[13]. - Administrative expenses for the year were approximately HKD 89.3 million, a 10.7% increase from the previous year[140]. - The company’s effective tax expense increased to HKD 57,356, compared to HKD 45,462 in the previous year[86]. Financial Position - The total non-current assets amounted to HKD 965,716,000, an increase from HKD 702,732,000 in 2022[41]. - The company’s total equity attributable to owners increased to HKD 1,134,776,000 from HKD 1,014,266,000[42]. - The company had cash and cash equivalents of approximately HKD 720.2 million as of December 31, 2023[141]. - The total assets of the group as of December 31, 2023, were HKD 1,753.6 million, compared to HKD 1,541.0 million in 2022[176]. - Non-current liabilities rose to HKD 417,624,000, compared to HKD 334,236,000 in 2022, indicating increased financial commitments[188]. Strategic Initiatives - The company plans to leverage its global clinic network to mitigate regional risks and enhance future growth prospects[1]. - The group plans to expand its existing operations in Mannheim, Germany, following the integration of FreeVis GmbH and PMK, enhancing its market leadership in Germany[26]. - The company plans to open satellite clinics in Beijing and Shanghai to enhance service utilization and penetrate high-potential markets[137]. - The company anticipates significant revenue growth contributions from new clinics in Wiesbaden and Kiel, expected to commence operations in the first half of 2024[111]. - The group is actively seeking acquisition opportunities, particularly targeting renowned private ophthalmology clinics in Europe and Asia, with a focus on emerging markets[153]. Market Performance - The revenue contribution from China increased significantly to 20.2% in 2023 from 16.1% in 2022, with revenue rising by 46.3% to HKD 144.0 million[4]. - In Denmark, revenue increased by 35.0% to HKD 87.9 million, with over 90% of revenue coming from resilient cataract surgeries[130]. - The company opened two new flagship clinics in 2023, one in Knightsbridge, London, and another in Causeway Bay, Hong Kong, enhancing market presence[100]. Governance and Compliance - The group has complied with the corporate governance code and has not separated the roles of Chairman and CEO, believing this structure enhances strategic effectiveness[30]. - The company has not pledged any assets as of December 31, 2023[21].
德视佳(01846) - 2023 - 年度业绩